研究报告 |
|
|
|
|
基于核酸适配体的肿瘤免疫治疗进展 * |
吕海银,王腾飞,裴仁军() |
中国科学院苏州纳米技术与纳米仿生研究所 纳米生物医学研究部 苏州 215123 |
|
Progress in Aptamer Based Tumor Immunotherapy |
Hai-yin LV,Teng-fei WANG,Ren-jun PEI() |
Suzhou Institute of Nano-Tech and Nano-Bionics(SINANO),Chinese Academy of Sciences, Division of Nanobiomedicine, Suzhou 215123,China |
[1] |
Johnson L A, June C H . Driving gene-engineered T cell immunotherapy of cancer. Cell Res, 2017,27(1):38-58.
|
[2] |
Yee C . Adoptive T cell therapy: points to consider. Curr Opin Immunol, 2018,51:197-203.
doi: 10.1016/j.coi.2018.04.007
|
[3] |
Ligtenberg M A, Pico De Coana Y, Shmushkovich T , et al. Self-delivering RNAi targeting PD-1 improves tumor-specific T cell functionality for adoptive cell therapy of malignant melanoma. Mol Ther, 2018,26(6):1482-1493.
doi: 10.1016/j.ymthe.2018.04.015
|
[4] |
Vormittag P, Gunn R, Ghorashian S , et al. A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol, 2018,53:164-181.
doi: 10.1016/j.copbio.2018.01.025
|
[5] |
Arabi F, Torabi-Rahvar M, Shariati A , et al. Antigenic targets of CAR T cell therapy. A retrospective view on clinical trials. Exp Cell Res, 2018,369(1):1-10.
doi: 10.1016/j.yexcr.2018.05.009
|
[6] |
Ramello M C, Haura E B, Abate-Daga D . CAR-T cells and combination therapies: What’s next in the immunotherapy revolution. Pharmacol Res, 2018,129:194-203.
doi: 10.1016/j.phrs.2017.11.035
|
[7] |
Khalil D N, Smith E L, Brentjens R J , et al. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol, 2016,13(5):273-290.
|
[8] |
Simpson A, Caballero O . Monoclonal antibodies for the therapy of cancer. BMC Proceedings, 2014,8(Suppl 4):6.
|
[9] |
Almagro J C, Daniels-Wells T R, Perez-Tapia S M , et al. Progress and challenges in the design and clinical development of antibodies for cancer therapy. Front Immunol, 2017,8:1751.
|
[10] |
Thomas A, Teicher B A, Hassan R . Antibody-drug conjugates for cancer therapy. The Lancet Oncology, 2016,17(6):e254-e262.
doi: 10.1016/S1470-2045(16)30030-4
|
[11] |
Nasiri H, Valedkarimi Z, Aghebati-Maleki L , et al. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy. J Cell Physiol, 2018,233(9):6441-6457.
doi: 10.1002/jcp.26435
|
[12] |
Krishnamurthy A, Jimeno A . Bispecific antibodies for cancer therapy: A review. Pharmacol Ther, 2018,185:122-134.
doi: 10.1016/j.pharmthera.2017.12.002
|
[13] |
Kontermann R E, Brinkmann U . Bispecific antibodies. Drug Discov Today, 2015,20(7):838-847.
doi: 10.1016/j.drudis.2015.02.008
|
[14] |
Klebanoff C A, Rosenberg S A, Restifo N P . Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med, 2016,22(1):26-36.
|
[15] |
Lyons J M, Schwimer J E, Anthony C T , et al. The role of VEGF pathways in human physiologic and pathologic angiogenesis. J Surg Res, 2010,159(1):517-527.
doi: 10.1016/j.jss.2008.12.014
|
[16] |
Groff K, Brown J, Clippinger A J . Modern affinity reagents: Recombinant antibodies and aptamers. Biotechnol Adv, 2015,33(8):1787-1798.
doi: 10.1016/j.biotechadv.2015.10.004
|
[17] |
Lee A, Sun S, Sandler A , et al. Recent progress in therapeutic antibodies for cancer immunotherapy. Curr Opin Chem Biol, 2018,44:56-65.
doi: 10.1016/j.cbpa.2018.05.006
|
[18] |
Zhou Z, Liu M, Jiang J . The potential of aptamers for cancer research. Anal Biochem, 2018,549:91-95.
doi: 10.1016/j.ab.2018.03.008
|
[19] |
Soldevilla M M, Villanueva H, Pastor F . Aptamers: A feasible technology in cancer immunotherapy. J Immunol Res, 2016,2016:1083738.
|
[20] |
Hu P P . Recent advances in aptamers targeting immune system. Inflammation, 2017,40(1):295-302.
doi: 10.1007/s10753-016-0437-9
|
[21] |
Kim M, Kim D M, Kim K S , et al. Applications of cancer cell-specific aptamers in targeted delivery of anticancer therapeutic agents. Molecules, 2018,23(4):830.
doi: 10.3390/molecules23040830
|
[22] |
Pastor F . Aptamers: A new technological platform in cancer immunotherapy. Pharmaceuticals 2016,9(4):64.
doi: 10.3390/ph9040064
|
[23] |
Wu X, Shaikh A B, Yu Y , et al. Potential diagnostic and therapeutic applications of oligonucleotide aptamers in breast cancer. Int J Mol Sci, 2017,18(9):1851.
doi: 10.3390/ijms18091851
|
[24] |
Ghahremani F, Shahbazi-Gahrouei D, Amirhosein Kefayat , et al. AS1411 aptamer conjugated gold nanoclusters as a targeted radiosensitizer for megavoltage radiation therapy of 4T1 breast cancer cells. RSC Advances, 2018,8(8):4249-4258.
doi: 10.1039/C7RA11116A
|
[25] |
Ai J, Ga L, Wang Y . A dual-targeting AS1411-folic acid fluorescent nanocomposite for cancer cell and drug delivery. Analytical Methods, 2018,10(17):1949-1951.
doi: 10.1039/C8AY00410B
|
[26] |
Yoon S, Huang K W, Reebye V , et al. Aptamer-drug conjugates ofactive metabolites of nucleoside analogs and cytotoxic agents inhibit pancreatic tumor cell growth. Mol Ther Nucleic Acids, 2017,6:80-88.
doi: 10.1016/j.omtn.2016.11.008
|
[27] |
Kong D H, Kim M R, Jang J H , et al. A review of anti-angiogenic targets for monoclonal antibody cancer therapy. Int J Mol Sci, 2017,18(8):1786.
doi: 10.3390/ijms18081786
|
[28] |
Zhang X, Peng L, Liang Z , et al. Effects of aptamer to U87-EGFRvIII cells on the proliferation, radiosensitivity, and radiotherapy of glioblastoma cells. Mol Ther Nucleic Acids, 2018,10:438-449.
doi: 10.1016/j.omtn.2018.01.001
|
[29] |
Morita Y, Leslie M, Kameyama H , et al. Aptamer therapeutics in cancer: Current and future. Cancers 2018,10(3):80.
doi: 10.3390/cancers10030080
|
[30] |
Prodeus A, Abdul-Wahid A, Fischer N W , et al. Targeting the PD-1/PD-L1 immune evasion axis with DNA aptamers as a novel therapeutic strategy for the treatment of disseminated cancers. Mol Ther Nucleic Acids, 2015,4:e237.
doi: 10.1038/mtna.2015.11
|
[31] |
Wang H, Lam C H, Li X , et al. Selection of PD1/PD-L1 X-aptamers. Biochimie, 2018,145:125-130.
doi: 10.1016/j.biochi.2017.09.006
|
[32] |
Lai W Y, Huang B T, Wang J W , et al. A novel PD-L1-targeting antagonistic DNA aptamer with antitumor effects. Mol Ther Nucleic Acids, 2016,5(12):e397.
|
[33] |
Huang B T, Lai W Y, Chang Y C , et al. A CTLA-4 antagonizing DNA aptamer with antitumor effect. Mol Ther Nucleic Acids, 2017,8:520-528.
doi: 10.1016/j.omtn.2017.08.006
|
[34] |
Pratico E D, Sullenger B A, Nair S K . Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40. Nucleic Acid Ther, 2013,23(1):35-43.
doi: 10.1089/nat.2012.0388
|
[35] |
Dollins C M, Nair S, Boczkowski D , et al. Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem Biol, 2008,15(7):675-682.
doi: 10.1016/j.chembiol.2008.05.016
|
[36] |
Liu X, Yan H, Liu Y , et al. Targeted cell-cell interactions by DNA nanoscaffold-templated multivalent bispecific aptamers. Small, 2011,7(12):1673-1682.
doi: 10.1002/smll.v7.12
|
[37] |
Rajagopalan A, Berezhnoy A, Schrand B , et al. Aptamer-targeted attenuation of IL-2 signaling in CD8 + T cells enhances antitumor immunity. Mol Ther, 2017,25(1):54-61.
doi: 10.1016/j.ymthe.2016.10.021
|
[38] |
Schrand B, Berezhnoy A, Brenneman R , et al. Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy. Cancer Immunol Res, 2014,2(9):867-877.
doi: 10.1158/2326-6066.CIR-14-0007
|
[39] |
Pastor F, Kolonias D, Mcnamara J O , et al. Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers. Mol Ther, 2011,19(10):1878-1886.
doi: 10.1038/mt.2011.145
|
[40] |
Pastor F . Tumor-targeted costimulation by using bi-specific aptamers. Cancer Cell Microenviron, 2016,3:e1333.
|
[41] |
Soldevilla M M, Villanueva H, Casares N , et al. MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells. Oncotarget, 2016,7(17):23182-23196.
|
[42] |
O’donnell J S, Smyth M J, Teng M W L . PD1 functions by inhibiting CD28-mediated co-stimulation. Clin Transl Immunology, 2017,6(5):e138.
doi: 10.1038/cti.2017.15
|
[43] |
Khedri M, Rafatpanah H, Abnous K , et al. Cancer immunotherapy via nucleic acid aptamers. Int Immunopharmacol, 2015,29(2):926-936.
doi: 10.1016/j.intimp.2015.10.013
|
[44] |
Alshaer W, Hillaireau H, Vergnaud J , et al. Aptamer-guided siRNA-loaded nanomedicines for systemic gene silencing in CD-44 expressing murine triple-negative breast cancer model. J Control Release, 2018,271:98-106.
doi: 10.1016/j.jconrel.2017.12.022
|
[45] |
De Almeida C E B, Alves L N, Rocha H F , et al. Aptamer delivery of siRNA, radiopharmaceutics and chemotherapy agents in cancer. Int J Pharm, 2017,525(2):334-342.
doi: 10.1016/j.ijpharm.2017.03.086
|
[46] |
Berezhnoy A, Castro I, Levay A , et al. Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity. J Clin Invest, 2014,124(1):188-197.
doi: 10.1172/JCI69856
|
[47] |
Heo K, Min S W, Sung H J , et al. An aptamer-antibody complex (oligobody) as a novel delivery platform for targeted cancer therapies. J Control Release, 2016,229:1-9.
doi: 10.1016/j.jconrel.2016.03.006
|
[48] |
Hu Z, He J, Gong W , et al. TLS11a aptamer/CD3 antibody anti-tumor system for liver cancer. J Biomed Nanotechnol, 2018,14(9):1645-1653.
doi: 10.1166/jbn.2018.2619
|
[49] |
Keefe A D, Pai S, Ellington A . Aptamers as therapeutics. Nat Rev Drug Discov, 2010,9(7):537-550.
doi: 10.1038/nrd3141
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|